|
|
CRL1005 |
|
Vaxjo ID |
29 |
|
Vaccine Adjuvant Name |
CRL1005 |
|
Adjuvant VO ID |
VO_0001318
|
|
Description |
The CRL1005 copolymer was designed to be soluble in aqueous, isotonic buffers below its cloud point, 2-8X, and to aggregate spontaneously into microparticles at higher temperatures (Todd et al., 1997). |
|
Stage of Development |
Clinical Trial |
|
Components |
A copolymer, based on a 12 kDa polyoxypropylene (POP) core with 5% POE (Katz et al., 2000). |
| Related Vaccine(s) |
|
| References |
Katz et al., 2000: Katz JM, Lu X, Todd CW, Newman MJ. A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine. 2000; 18(21); 2177-2187. [PubMed: 10717336].
Todd et al., 1997: Todd CW, Pozzi LA, Guarnaccia JR, Balasubramanian M, Henk WG, Younger LE, Newman MJ. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine. 1997; 15(5); 564-570. [PubMed: 9160526].
|
|
